Human urinary bladder-carcinoma cells are non-osteoinductive.
Small pieces (ca. 2-3 x 3-5 mm) of the urinary-tract mucosa from noninvasive papillary transitional-cell carcinomas of the bladder (ca. urotheliale papillare, n = 33), invasive transitional-cell carcinomas of the bladder (ca. urotheliale papillare infiltrans, n = 6, papillary transitional-cell carcinomas of the bladder with squamous metaplasia (ca. urotheliale papillare cum metaplasia planoepitheliale, n = 4), transitional-cell carcinomas in situ (ca. urotheliale in situ, n = 2), and squamous-cell carcinomas of the bladder (ca. planoepitheliale, n = 2) were grafted intramuscularly into cortisone-immunosuppressed mice to test the ability of transformed transitional epithelium to induce heterotopic osteogenesis. Altogether, 156 implants from 47 cases of urinary bladder carcinoma were performed. Histological examination of implants, excised 10-17 days later, revealed relatively good survival of the grafted epithelium, which had proliferated and, in some cases, formed cysts and islands but failed to induce heterotopic osteogenesis in the surrounding host tissues. In nine implants prepared from four cases (noninvasive papillary transitional-cell carcinoma of the bladder and invasive papillary transitional-cell carcinoma of the bladder, two cases each) a small amount of cartilage and/or bone was found in the stroma of grafted tissue. The rarity of this phenomenon--together with the observation that implants of normal human urinary-tract mucosa have never induced the formation of cartilage/bone, whereas in a similar system, dog or guinea-pig grafts are osteogenic--suggests that the cartilage/bone present in the stroma of implanted cancers is the result of metaplasia of the stroma of the neoplasm and not the product of any osteoinductive potency of human urothelium.
Włodarski
K H
KH
Department of Histology and Embryology, Institute of Biostructure, Medical School, Warsaw, Poland.
Kuzaka
B
B
Włodarski
P
P
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000503:physiopathology; D002295:Carcinoma, Transitional Cell / Q000473:pathology* / Q000503:physiopathology; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D010012:Osteogenesis / Q000502:physiology; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000503:physiopathology
D000305:Adrenal Cortex Hormones